EP0514015A1 — Control of sex differentiation in fish
Assigned to Merck and Co Inc · Expires 1992-11-19 · 33y expired
What this patent protects
Fish or shellfish eggs, fertilized embryos or hatched fry or shellfish are treated with steroid biosynthesis inhibitors or antagonists which prevents the conversion of androgens to estrogens. By blocking the production of estrogens the genotypic female is converted into a phenoty…
USPTO Abstract
Fish or shellfish eggs, fertilized embryos or hatched fry or shellfish are treated with steroid biosynthesis inhibitors or antagonists which prevents the conversion of androgens to estrogens. By blocking the production of estrogens the genotypic female is converted into a phenotypic male. The phenotypic conversion of females to males gives the treated fish the advantage of male growth characteristics. Such treatment will also allow the production of monosex populations of fish which can be used to limit reproduction and control overpopulation of specific aquatic environments. Steroid biosynthesis inhibitors and/or antagonists will also induce smoltification in salmon species.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.